Event-Related Potential Responses to Beloved and Familiar Faces in Different Marriage Styles: Evidence from Mosuo Subjects

Research on familiar face recognition has largely focused on the neural correlates of recognizing a beloved partner or family member. However, no research has explored the effect of marriage style on the recognition of a beloved partner's face, especially in matriarchal societies. Here, we examined the time course of event-related potentials (ERP) in response to the face of a beloved partner, sibling, or unknown person in a sample of individuals from the matriarchal Mosuo tribe. Two groups were assessed: intermarriage and walking marriage groups (i.e., couples in a committed relationship who do not cohabitate during the daytime). In agreement with previous reports, ERP results revealed more positive VPP, N250, and P300 waveforms for beloved faces than sibling faces in both groups. Moreover, P300 was more positive for beloved partner versus sibling faces; however, this difference emerged at fronto-central sites for the walking marriage group and at posterior sites for the intermarriage group. Overall, we observed that marriage style affects the later stage processing of a beloved partner's face, and this may be associated with greater affective arousal and familiarity

Genome-wide study of response to platinum, taxane, and combination therapy in ovarian cancer: in vitro phenotypes, inherited variation, and disease recurrence

Abstract:Background: The standard treatment for epithelial ovarian cancer (EOC) patients with advanced disease is carboplatin-paclitaxel combination therapy following initial debulking surgery, yet there is wide inter-patient variation in clinical response. We sought to identify pharmacogenomic markers related to carboplatin-paclitaxel therapy. Methods: The lymphoblastoid cell lines, derived from 74 invasive EOC patients seen at the Mayo Clinic, were treated with increasing concentrations of carboplatin and/or paclitaxel and assessed for in vitro drug response using MTT viability and caspase3/7 apoptosis assays. Drug response phenotypes IC50 (effective dose at which 50% of cells are viable) and EC50 (dose resulting in 50 % induction of caspase 3/7 activity) were estimated for each patient to paclitaxel and carboplatin (alone and in combination). For each of the six drug response phenotypes, a genome-wide association study was conducted. Results: Statistical analysis found paclitaxel in vitro drug response phenotypes to be moderately associated with time to EOC recurrence (p = 0.008 IC50; p = 0.058 EC50). Although no pharmacogenomic associations were significant at p <5x10-8, seven genomic loci were associated with drug response at p < 10-6, including at 4q21.21 for carboplatin, 4p16.1 and 5q23.2 for paclitaxel, and 3q24, 10q, 1q44, and 13q21 for combination therapy. Nearby genes of interest include FRAS1, MGC32805, SNCAIP, SLC9A9, TIAL1, ZNF731P, and PCDH20. Conclusions: These results suggest the existence of genetic loci associated with response to platinum-taxane therapies. Further research is needed to understand the mechanism by which these loci may impact EOC clinical response to this commonly used regimen